GILD vs MAIN · P/E 18, rev $29.44B vs P/E 10, $5.44B cap
Gilead Sciences Inc (GILD) versus Main Street Capital Corporation (MAIN) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
Main Street Capital Corporation (MAIN) is a asset management company listed on US.
Latest reported GILD revenue for 2025-12-31 was $29.44B. Net income was $8.51B. Revenue was up 2.4% from 2024-12-31 to 2025-12-31. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
MAIN does not have a complete income-statement cache yet.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. MAIN currently screens at market cap $5.44B and trailing P/E 10.4.
Not investment advice. Open the GILD and MAIN stock pages for the full models.
Not investment advice.